Skip to main content

Table 1 Effect of CL on basic parameters and TAC concentration

From: Cilastatin protects against tacrolimus-induced nephrotoxicity via anti-oxidative and anti-apoptotic properties

 

VH

VH + CL75

VH + CL150

TAC

TAC + CL75

TAC + CL150

BW (g)

79 ± 5

77 ± 9

83 ± 5

59 ± 6#

48 ± 6#

48 ± 4#

UV (mL/day)

9 ± 2

13 ± 1

25 ± 1#

26 ± 3#

31 ± 7#

22 ± 3#

WI (mL/day)

15 ± 3

18 ± 3

30 ± 3#

30 ± 3#

34 ± 7#

26 ± 3#

Scr (mg/dL)

0.35 ± 0.07

0.32 ± 0.02

0.32 ± 0.03

0.64 ± 0.05#

0.49 ± 0.02@

0.38 ± 0.05@

BUN (mg/dL)

14.1 ± 3.1

14 ± 1.4

14.2 ± 0.7

56.2 ± 6.9#

45.5 ± 1.4@

42.9 ± 4.5@

UMA (μg/mg)

1.6 ± 0.2

2.3 ± 0.2

2.4 ± 0.2

9.2 ± 1.2#

7.7 ± 1.3

4.8 ± 1.0@

CrCl (mL/min/100 g)

0.77 ± 0.13

0.76 ± 0.06

0.81 ± 0.11

0.35 ± 0.02#

0.50 ± 0.03@

0.62 ± 0.08@

TAC con.in blood (ng/mL)

_

_

_

14.1 ± 2.4

13.5 ± 2.1

13.9 ± 1.9

TAC con.in kidney (pg/mg)

_

_

_

7.4 ± 1.3

6.3 ± 1.1

5.1 ± 1.6

  1. #P < 0.05 vs. VH
  2. @P < 0.05 vs. TAC
  3. BW body weight, UV urine volume, WI Water intake, Scr serum creatinine, BUN blood urea nitrogen, UMA urine microalbumin, CrCl creatinine clearance, TAC con. tacrolimus concentration, VH vehicle, TAC tacrolimus; CL75 and CL150, 75 and 150 mg/kg of CL values are means ± standard error